The client is seeking an Interim-Chief Medical Officer for their privately-held biotech firm in the USA, with a focus on addressing unmet medical needs related to hematological diseases. This role involves providing senior oversight for Phase III trial operations across the United States. Key responsibilities include guiding contract research organizations (CROs) and site management, monitoring enrollment progress, implementing risk mitigation strategies, supporting clinical strategy and safety oversight, and facilitating engagement with investigators and key opinion leaders (KOLs). Collaboration with regulatory and clinical teams is essential for executing FDA-ready submissions.
The ideal candidate will have an MD and significant clinical development leadership experience within the relevant therapeutic area, particularly in hematology/oncology. A proven track record of leading Phase III trials and strong understanding of FDA expectations, Good Clinical Practice (GCP), and U.S. trial operations is crucial. Prior experience as a Chief Medical Officer or Vice President of Clinical Development is preferred. This fractional role requires a commitment of 10-15 hours per week, 4 weeks per month, over a 24-month contract period. The position is based in New Jersey, with the expectation for some work to be completed onsite.
In return, the client offers a competitive hourly rate, translating to an annual range of $200,000 to $250,000 USD, within a collaborative and innovative work environment. This opportunity is ideal for professionals seeking a rewarding challenge in a fractional medical advisory capacity. Candidates ready to make a significant impact in the field of hematology are encouraged to apply for this compelling role.